Subscribe to RSS
DOI: 10.1055/s-2007-992115
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York
The European Perspective of Type 2 Diabetes Prevention: Diabetes in Europe - Prevention Using Lifestyle, Physical Activity and Nutritional Intervention (DE-PLAN) Project
Publication History
received 27.09.2007
first decision 27.09.2007
accepted 27.09.2007
Publication Date:
19 March 2008 (online)
Abstract
Background: The prevalence of type 2 diabetes (T2D) has dramatically increased in Europe, and the age-at-diagnosis has become younger. Action is needed now to develop targeted prevention management program for T2D. The DE-PLAN (“Diabetes in Europe - Prevention using Lifestyle, Physical Activity and Nutritional intervention”) project, led by the University of Helsinki is currently addressing this major public health concern in Europe.
Methods: The DE-PLAN project aims at developing and testing models of efficient identification and intervention of individuals at high risk of type 2 diabetes in the community. It conducts a lifestyle modification intervention in people at high risk for T2D. Furthermore, it tests the feasibility and cost-effectiveness of the translation of the current research evidence about preventive intervention program into clinical settings within existing health care systems in 17 European countries.
Results: This 3-year project spanning has commenced mid-2005. By now, 25 institutions from 17 countries are involved.
Conclusion: The development of efficient screening strategies for type 2 diabetes risk as well as the development of core intervention strategies for the primary prevention of type 2 diabetes should significantly enhance the ability of health care professionals to respond swiftly to the drastic increase of T2D and its burden to the society.
Key words
type 2 diabetes - prevention - screening - FINDRISC - intervention program - quality standards - cost-effectiveness
References
- 1 King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998; 21 ((9)) 1414-1431
- 2 Schwarz PE. Congress report from the American Diabetes Association 66th Annual Scientific Sessions in Washington, USA. Exp Clin Endocrinol Diabetes. 2006; 114 ((10)) 605-610
- 3 Schwarz PE. Report from the Congress of the American Diabetes Association (ADA): Orlando 2005-65th Annual Scientific Sessions in San Diego, CA, USA, June 10th-14th 2005. Exp Clin Endocrinol Diabetes. 2005; 113 ((8)) 475-479
- 4 The DECODE Study Group (Tuomilehto J) . Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003; 26 ((1)) 61-69
-
5
Diabetes Atlas, ed. I.D. Federation .
, Vol. 3.
2006;
, International Diabetes Federation
- 6 Valensi P. et al . Pre-diabetes essential action: a European perspective. Diabetes Metab. 2005; 31 ((6)) 606-620
- 7 Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001; 414 ((6865)) 782-787
- 8 Kulzer B. Diabetes mellitus: how important is it to measure the quality of life?. Dtsch Med Wochenschr. 2006; 131 ((Suppl 8)) S259-S263
- 9 Glucose tolerance and mortality: comparison of WHO. American Diabetes Association diagnostic criteria. The DECODE study group . European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet. 1999; 354 ((9179)) 617-621
- 10 Lindgren P. et al . Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective. Int J Technol Assess Health Care. 2007; 23 ((2)) 177-183
- 11 Roglic G. et al . The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005; 28 ((9)) 2130-2135
- 12 Matthews DR, Pramming S. Diabetes and the global burden of non-communicable disease. Lancet. 2003; 362 ((9397)) 1763-1764
- 13 Trajkovski M. et al . Genes of type 2 diabetes in Beta cells. Endocrinol Metab Clin North Am. 2006; 35 ((2)) 357-369
- 14 Schwarz PE. et al . Hypoadiponectinemia is associated with progression toward type 2 diabetes and genetic variation in the ADIPOQ gene promoter. Diabetes Care. 2006; 29 ((7)) 1645-1650
- 15 Schwarz PE, Bornstein SR. Pre-diabetes and metabolic syndrome in Germans. Horm Metab Res. 2006; 38 ((5)) 359
- 16 Hanefeld M. et al . The metabolic syndrome-a postprandial disease?. Horm Metab Res. 2006; 38 ((7)) 435-436
- 17 Steyn NP. et al . Diet, nutrition and the prevention of type 2 diabetes. Public Health Nutr. 2004; 7 ((1A)) 147-165
- 18 Lindstrom J, Peltonen M, Tuomilehto J. Lifestyle strategies for weight control: experience from the Finnish Diabetes Prevention Study. Proc Nutr Soc. 2005; 64 ((1)) 81-88
- 19 Hu G. et al . Physical activity, physical fitness and the risk of type 2 diabetes. Metabolic Syndrome Rel Disorders. 2005; 3 35-44
- 20 Hanefeld M. et al . The challenge of the metabolic syndrome. Horm Metab Res. 2007; 39 ((9)) 625-626
- 21 Diamantopoulos EJ. et al . Metabolic syndrome and prediabetes identify overlapping but not identical populations. Exp Clin Endocrinol Diabetes. 2006; 114 ((7)) 377-383
- 22 Haffner SM. et al . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339 ((4)) 229-234
- 23 Miettinen H. et al . Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care. 1998; 21 ((1)) 69-75
- 24 Schwarz PE. et al . Diabetes prevention-from physiology to implementation. Horm Metab Res. 2006; 38 ((7)) 460-464
- 25 Ottelin AM. et al . Costs of a self-selected, health-promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care. 2007; 30 ((5)) 1275-1277
- 26 Knowler WC. et al . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346 ((6)) 393-403
- 27 Tuomilehto J. et al . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344 ((18)) 1343-1350
- 28 Chiasson JL. et al . Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002; 359 ((9323)) 2072-2077
- 29 Pan XR. et al . Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997; 20 ((4)) 537-544
- 30 Snitker S. et al . Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care. 2004; 27 ((6)) 1365-1368
- 31 Torgerson JS. et al . XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004; 27 ((1)) 155-161
- 32 Bosch J. et al . Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006; 355 ((15)) 1551-1562
- 33 Lindstrom J. et al . Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006; 368 ((9548)) 1673-1679
- 34 Zimmet P. The burden of type 2 diabetes: are we doing enough?. Diabetes Metab. 2003; 29 ((4 Pt 2)) 6S9-618
- 35 Schwarz PE. et al . Development of a diabetes prevention management program for clinical practice. Public Health Rep. 2007; 122 ((2)) 258-263
- 36 Hall M. et al . Diabetes- The Policy Puzzle: Towards Benchmaking in the EU 25. International Diabetes Federation European Region and Federation of European Nurses in Diabetes. 2005; 103
- 37 Saaristo T. et al . National type 2 diabetes prevention programme in Finland: FIN-D2D. Int J Circumpolar Health. 2007; 66 ((2)) 101-112
- 38 Lindstrom J, Tuomilehto J. The Diabetes Risk Score: A practical tool to predict type 2 diabetes risk. Diabetes Care. 2003; 26 ((3)) 725-731
- 39 Saaristo T. et al . Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diab Vasc Dis Res. 2005; 2 ((2)) 67-72
- 40 Schwarz P. Targeted diabetes prevention in high risk groups: pro. Dtsch Med Wochenschr. 2005; 130 ((17)) 1103
- 41 Silventoinen K. et al . The validity of the Finnish Diabetes Risk Score for the prediction of the incidence of coronary heart disease and stroke, and total mortality. Eur J Cardiovasc Prev Rehabil. 2005; 12 ((5)) 451-458
- 42 Schwarz PEH. et al . An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes, response to Schulze et al. Diabetes Care. 2007; 30 ((8)) e87
- 43 Bergmann A. et al . A simplified finnish diabetes risk score to predict type 2 diabetes risk and disease evolution in a german population. Horm Metab Res. 2007; 39 ((9)) 677-682
- 44 Schwarz PE, Bornstein SR, Hanefeld M. Elevated fasting glucose levels predicts IGT and diabetes also in middle-age subjects. Diabetes Res Clin Pract. 2007; 77 ((1)) 148-150
- 45 Mielck A, Reitmeir P, Rathmann W. Knowledge about diabetes and participation in diabetes training courses: the need for improving health care for diabetes patients with low SES. Exp Clin Endocrinol Diabetes. 2006; 114 ((5)) 240-248
- 46 Schwarz PEH. et al . Prevention of type 2 diabetes: what challenges do we have to address?. Journal of Public Health. 2005; 13 ((2)) 303-308
- 47 Roubideaux Y. et al . Measuring the quality of diabetes care for older american indians and alaska natives. Am J Public Health. 2004; 94 ((1)) 60-65
- 48 Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003; 26 ((9)) 2518-2523
- 49 Hernan WH. et al . Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care. 2003; 26 ((1)) 36-47
- 50 Qiao Q, Tuomilehto J. Diagnostic criteria of glucose intolerance and mortality. Minerva Med. 2001; 92 ((2)) 113-119
- 51 Schwarz PE, Peltonen M. Prevention of type 2 diabetes - lessons we have learnt for implementation. Horm Metab Res. 2007; 39 ((9)) 636-641
Correspondence
Dr. P. E. H. Schwarz
Department of Medicine III
Medical Faculty Carl-Gustav-Carus
Technical University Dresden
01307 Dresden
Germany
Phone: +49/351/458 27 15
Fax: +49/351/458 73 19
Email: peter.schwarz@uniklinikum-dresden.de